Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Total Current Liabilities (2020 - 2025)

Bolt Biotherapeutics' Total Current Liabilities history spans 6 years, with the latest figure at $10.0 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 44.89% year-over-year to $10.0 million; the TTM value through Sep 2025 reached $10.0 million, down 44.89%, while the annual FY2024 figure was $15.9 million, 22.49% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $10.0 million at Bolt Biotherapeutics, down from $12.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $24.2 million in Q3 2022 and bottomed at $10.0 million in Q3 2025.
  • The 5-year median for Total Current Liabilities is $18.1 million (2024), against an average of $17.8 million.
  • The largest annual shift saw Total Current Liabilities surged 89.35% in 2021 before it crashed 44.89% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $21.3 million in 2021, then rose by 8.39% to $23.1 million in 2022, then decreased by 11.51% to $20.5 million in 2023, then dropped by 22.49% to $15.9 million in 2024, then plummeted by 37.15% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Total Current Liabilities are $10.0 million (Q3 2025), $12.3 million (Q2 2025), and $13.6 million (Q1 2025).